Wednesday, July 2, 2025 7/2/2025

Development of an ETEC multivalent subunit vaccine using outer membrane vesicles

Award Number: R21AI190682
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Development of an ETEC multivalent subunit vaccine using outer membrane vesicles - Project Summary Vaccines are one of the most important medical interventions in history, yet no vaccines exist that protect against enterotoxigenic Escherichia coli (ETEC) - one of the major diarrheagenic pathogens in children in low-resource settings. ETEC pathogenesis begins with fecal-oral dissemination, attachment to the small intestinal epithelium via colonization factors (CFs), and elaboration of the heat-labile (LT) and heat-stable (ST) enterotoxins. The majority of ETEC vaccine efforts have focused primarily on generation of protective immune responses to CFs and LT, and vaccine antigens that provide coverage to ST are a critical gap in achieving full vaccine protection. Addressing this gap is imperative since large epidemiological studies have shown that ST is associated with the most severe cases of ETEC diarrheal disease. Here we will test the central hypothesis that immunization with outer membrane vesicle (OMV)-adjuvanted multivalent vaccines can establish anti-ETEC immunity in the gastrointestinal tract, where it is needed to neutralize enterotoxins and block bacterial colonization. Our hypothesis is supported by preliminary data demonstrating that OMV-adjuvanted ST and OMV-adjuvanted CFs induce ST- and CF-specific antibodies, respectively. Studies in Aim 1 will test the hypothesis that antibodies produced following immunization with OMV-adjuvanted ST and LT toxoids will protect against toxin-mediated secretory diarrhea. Studies in Aim 2 will test the hypothesis that antibodies produced following immunization with OMV-adjuvanted CFs will prevent ETEC colonization of the small intestinal epithelium. Development of an effective multivalent vaccine against ETEC would have a major impact on public health by reducing the global burden of bacterial diarrhea.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $185,513 )
2025	2025	THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND	6823 SAINT CHARLES AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Allergy and Infectious Diseases Research	000	1	2/25/2025	NEW	$185,513
														Subtotal = $185,513

Grand Total All Awards = $185,513

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of an ETEC multivalent subunit vaccine using outer membrane vesicles

Award Number: R21AI190682

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer